Article
Dynamics of HCV genotype 4 resistance-associated variants during virologic escape with pIFN/RBV+daclatasvir: a case study using ultra deep pyrosequencing.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology - 1 May 2015
Bartolini Barbara, Lionetti Raffaella, Giombini Emanuela, Sias Catia, Taibi Chiara, Montalbano Marzia, D'Offizi Gianpiero, Gianpiero D'Offizi, McPhee Fiona, Hughes Eric A, Zhou Nannan, Ippolito Giuseppe, Garbuglia Anna Rosa, Capobianchi Maria R
Abstract excerpt
BACKGROUND: Daclatasvir (DCV) is an approved NS5A inhibitor with potent anti-HCV activity and broad genotype coverage. DCV resistance-associated variants (RAVs) have been described for patients infected with genotype (GT) 1, but increased GT4 prevalence in European countries as a result of immigration has boosted interest in this genotype. OBJECTIVES: Establishment of NS5A variability in treatment-naive patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
